CareDx (NASDAQ:CDNA) Director Sells $279,700.33 in Stock

CareDx, Inc. (NASDAQ:CDNA) Director Hannah Valantine sold 12,103 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the sale, the director directly owned 36,686 shares of the company’s stock, valued at approximately $847,813.46. This trade represents a 24.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CareDx Price Performance

Shares of CDNA opened at $26.18 on Friday. CareDx, Inc. has a 12 month low of $10.96 and a 12 month high of $26.26. The stock’s 50-day moving average is $21.31 and its two-hundred day moving average is $19.80. The stock has a market cap of $1.35 billion, a PE ratio of -163.62 and a beta of 2.49.

CareDx (NASDAQ:CDNA) last announced its earnings results on Tuesday, April 28th. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.11 by $0.23. CareDx had a negative return on equity of 2.65% and a negative net margin of 2.01%.The business had revenue of $117.70 million for the quarter, compared to the consensus estimate of $102.03 million. During the same period last year, the business posted $0.09 EPS. The company’s revenue was up 39.3% on a year-over-year basis. On average, research analysts anticipate that CareDx, Inc. will post 0.22 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on CDNA shares. Wells Fargo & Company boosted their price objective on shares of CareDx from $18.00 to $21.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. BTIG Research lifted their target price on CareDx from $26.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Weiss Ratings reiterated a “sell (d)” rating on shares of CareDx in a research note on Wednesday, May 27th. Finally, Wall Street Zen raised CareDx from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 3rd. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, CareDx presently has an average rating of “Hold” and an average price target of $25.00.

Institutional Trading of CareDx

Several hedge funds and other institutional investors have recently bought and sold shares of CDNA. First Eagle Investment Management LLC grew its position in shares of CareDx by 25.4% during the third quarter. First Eagle Investment Management LLC now owns 475,146 shares of the company’s stock worth $6,909,000 after acquiring an additional 96,123 shares during the last quarter. Paragon Associates & Paragon Associates II Joint Venture lifted its position in CareDx by 93.7% in the 3rd quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 425,000 shares of the company’s stock valued at $6,180,000 after purchasing an additional 205,597 shares during the last quarter. Aberdeen Group plc bought a new stake in CareDx in the 4th quarter valued at about $6,506,000. ARK Investment Management LLC boosted its stake in CareDx by 3.4% during the 3rd quarter. ARK Investment Management LLC now owns 2,170,625 shares of the company’s stock valued at $31,561,000 after purchasing an additional 70,468 shares during the period. Finally, Zweig DiMenna Associates LLC boosted its stake in CareDx by 153.8% during the 3rd quarter. Zweig DiMenna Associates LLC now owns 575,000 shares of the company’s stock valued at $8,360,000 after purchasing an additional 348,400 shares during the period.

CareDx Company Profile

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non?invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post?transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor?derived cell?free DNA assay used primarily in kidney transplant monitoring.